Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Five-year deal sees orthopedic expansion
November 2015
SHARING OPTIONS:

HAIFA, Israel—Pluristem Therapeutics Inc. and the Berlin-Brandenburg Center for Regenerative Therapy at Charité–University Medicine Berlin have expanded their five-year collaboration research agreement to include the identification of orthopedic indications that could be eligible for development under Europe’s Adaptive Pathways and conditional marketing approval in the EU. So far, the partners have completed an orthopedic Phase 1/2 study of PLacental eXpanded (PLX) cells in muscle injury. Pluristem and Charité have collaborated in other indications as well, including kidney diseases, cardiovascular indications and comprehensive immunological research for Pluristem’s peripheral artery disease clinical programs.
 
“In our studies, PLX cells demonstrated the potential to improve overall muscle functionality, with an impressive magnitude of effect. An additional orthopedic PLX indication has a promising potential,” said Dr. Tobias Winkler of the Center for Musculoskeletal Surgery & Julius Wolff Institute Berlin, Charité, who served as senior scientist for the Phase 1/2 study.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.